G
GemPharmatech Co Ltd
SSE:688046
GemPharmatech Co Ltd
SSE:688046
Price:
18.65
CNY
-1.22%
Market Closed
Market Cap:
¥3.8B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
G
|
GemPharmatech Co Ltd
SSE:688046
|
CN |
|
P
|
Prysmian SpA
OTC:PRYMY
|
IT |
|
BYD Electronic International Co Ltd
HKEX:285
|
CN |
|
R
|
Redefine Properties Ltd
JSE:RDF
|
ZA |
Income Statement
Earnings Waterfall
GemPharmatech Co Ltd
GemPharmatech Co Ltd
Income Statement
GemPharmatech Co Ltd
GemPharmatech Co Ltd
Currency: CNY
| Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||
| Interest Expense |
1
|
1
|
1
|
0
|
0
|
1
|
1
|
2
|
3
|
3
|
4
|
4
|
4
|
4
|
0
|
0
|
|
| Revenue |
394
N/A
|
433
+10%
|
466
+8%
|
500
+7%
|
517
+3%
|
541
+5%
|
562
+4%
|
585
+4%
|
622
+6%
|
639
+3%
|
667
+4%
|
677
+2%
|
687
+1%
|
701
+2%
|
721
+3%
|
753
+4%
|
|
| Gross Profit | |||||||||||||||||
| Cost of Revenue |
(101)
|
(109)
|
(119)
|
(136)
|
(150)
|
(166)
|
(181)
|
(187)
|
(203)
|
(214)
|
(232)
|
(250)
|
(261)
|
(275)
|
(278)
|
(287)
|
|
| Gross Profit |
293
N/A
|
324
+11%
|
347
+7%
|
364
+5%
|
366
+1%
|
375
+2%
|
381
+2%
|
398
+4%
|
419
+5%
|
424
+1%
|
435
+2%
|
427
-2%
|
426
0%
|
425
0%
|
443
+4%
|
465
+5%
|
|
| Operating Income | |||||||||||||||||
| Operating Expenses |
(163)
|
(180)
|
(183)
|
(202)
|
(204)
|
(232)
|
(246)
|
(267)
|
(264)
|
(296)
|
(302)
|
(311)
|
(307)
|
(321)
|
(337)
|
(340)
|
|
| Selling, General & Administrative |
(143)
|
(158)
|
(167)
|
(175)
|
(183)
|
(186)
|
(194)
|
(199)
|
(212)
|
(218)
|
(225)
|
(235)
|
(247)
|
(245)
|
(250)
|
(253)
|
|
| Research & Development |
(55)
|
(62)
|
(70)
|
(79)
|
(83)
|
(89)
|
(95)
|
(97)
|
(94)
|
(95)
|
(87)
|
(84)
|
(82)
|
(82)
|
(86)
|
(86)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
(5)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
35
|
40
|
54
|
51
|
62
|
43
|
43
|
29
|
44
|
17
|
10
|
8
|
27
|
7
|
(1)
|
(1)
|
|
| Operating Income |
130
N/A
|
144
+11%
|
163
+14%
|
162
-1%
|
162
+0%
|
143
-12%
|
135
-5%
|
131
-3%
|
155
+18%
|
129
-17%
|
132
+3%
|
116
-12%
|
119
+2%
|
104
-12%
|
106
+2%
|
125
+18%
|
|
| Pre-Tax Income | |||||||||||||||||
| Interest Income Expense |
14
|
13
|
21
|
29
|
25
|
29
|
27
|
21
|
29
|
31
|
27
|
23
|
22
|
17
|
13
|
15
|
|
| Non-Reccuring Items |
0
|
(0)
|
(0)
|
(0)
|
(13)
|
0
|
(0)
|
(0)
|
(20)
|
0
|
0
|
(0)
|
(21)
|
(0)
|
(0)
|
(0)
|
|
| Total Other Income |
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(2)
|
(2)
|
(2)
|
(2)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Pre-Tax Income |
143
N/A
|
157
+10%
|
184
+17%
|
190
+3%
|
174
-9%
|
171
-1%
|
162
-5%
|
152
-6%
|
161
+6%
|
157
-3%
|
157
+0%
|
136
-13%
|
119
-13%
|
122
+2%
|
119
-2%
|
140
+18%
|
|
| Net Income | |||||||||||||||||
| Tax Provision |
(18)
|
(20)
|
(24)
|
(23)
|
(9)
|
(6)
|
(1)
|
2
|
(2)
|
0
|
1
|
3
|
(9)
|
(11)
|
(15)
|
(19)
|
|
| Income from Continuing Operations |
125
|
137
|
160
|
168
|
165
|
165
|
161
|
154
|
159
|
157
|
158
|
139
|
110
|
110
|
104
|
122
|
|
| Net Income (Common) |
125
N/A
|
137
+10%
|
160
+17%
|
168
+5%
|
165
-2%
|
165
+0%
|
161
-3%
|
154
-4%
|
159
+3%
|
157
-1%
|
158
+0%
|
139
-12%
|
110
-21%
|
110
+0%
|
104
-5%
|
122
+16%
|
|
| EPS (Diluted) |
0.3
N/A
|
0.33
+10%
|
0.39
+18%
|
0.41
+5%
|
0.4
-2%
|
0.4
N/A
|
0.39
-3%
|
0.38
-3%
|
0.39
+3%
|
0.38
-3%
|
0.39
+3%
|
0.34
-13%
|
0.27
-21%
|
0.27
N/A
|
0.25
-7%
|
0.3
+20%
|
|
Switch to:
Switch to:
See Also
Discover More
